Dr. Neil Riordan is the founder and Chairman of Medistem Panama, Inc., a leading stem cell laboratory and research facility located in the Technology Park of the prestigious City of Knowledge in Panama City, Panama. Medistem Panama, which was founded in 2007, is at the forefront of research of the effects of adult stem cells on the course of several chronic diseases. The stem cell laboratory at Medistem Panama is a fully licensed by the Ministry of Health of Panama.
He has more than 60 scientific articles in international peer-reviewed journals. In the stem cell arena, he and his colleagues have published more than 20 articles on Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis, Duchenne Muscular Dystrophy, Autism, and Charcot Marie Tooth Syndrome. In 2007, Dr. Riordan’s research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery his team was honored with the “Medical Article of the Year Award” from Biomed Central. Other notable journals in which Dr. Riordan has published articles include the British Journal of Cancer, Cellular Immunology, Journal of Immunotherapy, and Translational Medicine.
Riordan has authored two book chapters on the use of non-controversial stem cells from placenta and umbilical cord. He is also an established inventor as and inventor or co-inventor on more than 25 patent families, including 11 issued patents.
Dr. Neil Riordan’s team collaborates with a number of universities and institutions, including National Institutes of Health, Indiana University, University of California, San Diego, University of Utah, University of Western Ontario, and University of Nebraska.
Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals. His team developed the product Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.
Dr. Neil Riordan has made a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin C’s preferential toxicity to cancer cells notably led to a 1997 patent for the treatment of cancer with vitamin C being granted. In 2010, Dr. Riordan was granted an additional patent for a new cellular vaccine for patients with cancer.
Dr. Neil Riordan earned his Bachelor of Science at Wichita State University and graduated magna cum laude. He received his Master’s degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.